Alpha 2.0
Login Register
» Articles » PMID: 18285760

Bevacizumab in Combination with Irinotecan for Patients with Recurrent Glioblastoma Multiforme

Overview
Journal Nat Clin Pract Oncol
Specialty Oncology
Date 2008 Feb 21
PMID 18285760
Citations 6
Authors
David Schiff
Benjamin Purow
Affiliations
Soon will be listed here.
Citing Articles

Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.

Lieberman F F1000Res. 2017; 6:1892.

PMID: 29263783 PMC: 5658706. DOI: 10.12688/f1000research.11493.1.

Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review.

Su J, Cai M, Li W, Hou B, He H, Ling C Oncol Res. 2016; 24(2):117-28.

PMID: 27296952 PMC: 7838606. DOI: 10.3727/096504016X14612603423511.

Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment.

Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R Biomed Res Int. 2015; 2015:215135.

PMID: 26448930 PMC: 4584033. DOI: 10.1155/2015/215135.

Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Ellingson B, Kim H, Woodworth D, Pope W, Cloughesy J, Harris R Radiology. 2014; 271(1):200-10.

PMID: 24475840 PMC: 4263651. DOI: 10.1148/radiol.13131305.

Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

Armstrong T, Wen P, Gilbert M, Schiff D Neuro Oncol. 2012; 14(10):1203-14.

PMID: 22307472 PMC: 3452334. DOI: 10.1093/neuonc/nor223.